ATAI Investor Day Presentation Deck slide image

ATAI Investor Day Presentation Deck

CIAS phase 2a result summary Extension of prior clinical data to CIAS Safe and well-tolerated in SZ population Dose dependent, widespread qEEG changes across brain regions EO - Increased alpha/ASI (middle & high doses), decreased beta (lowest dose) ● ● ● ● EC - Observed elevations in resting state alpha, increased ASI, and decreased TBR Suggesting a relaxed wakeful state without drowsiness at the mid to high dose levels ERP data suggests some dose-dependent cognition relevant changes Evidence of bell-shaped dose-response HVLT-R immediate recall effect size = 0.44 (20 mg) Symbol coding effect size -0.4-0.8 atai LIFE SCIENCES ● ● "Symbol coding response is at a level that would correlate with better work/school performance" – Keith Nuechterlein | 40
View entire presentation